Why should we bother? Ethical and social issues in individualized medicine

Current Drug Targets

Volumn 7, Issue 12, 2006, Pages 1721-1727

  Paul, Norbert W ^a   Fangerau, Heiner ^b  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Clinical trials; Depression; Ethics; Individualized medicine; Pharmacogenetics; Pharmacogenomics

Indexed keywords

ANTIDEPRESSANT AGENT; APOLIPOPROTEIN E4; CARRIER PROTEIN; CYTOCHROME P450; DRUG; DRUG METABOLIZING ENZYME; NEUROTRANSMITTER RECEPTOR; PSYCHOTROPIC AGENT;

ALZHEIMER DISEASE; CLINICAL PRACTICE; CLINICAL STUDY; DEPRESSION; DRUG COST; DRUG RESEARCH; ECONOMIC ASPECT; ECONOMIC EVALUATION; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; MEDICAL ETHICS; MENTAL DISEASE; PATIENT ASSESSMENT; PHARMACOGENETICS; PHARMACOGENOMICS; PHENOTYPE; PRESCRIPTION; REVIEW; SOCIAL PSYCHOLOGY;

ETHICS, MEDICAL; HUMANS; PHARMACOGENETICS; SOCIAL RESPONSIBILITY; SOCIAL VALUES;

EID: 33845324822     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945006779025428     Document Type: Review

References (71)

1. Lazarou, J., Pomeranz, B.H., Corey, P.N. (1998) JAMA, 279, 1200-1205.
2. Emilien, G., Ponchon, M., Caldas, C., Isacson, O., Maloteaux, J.-M. (2000) Quart. J. Med., 93, 391-423.
3. Weatherall, D. (1999) Philos. Trans. R. Soc. Lond B. Biol. Sci., 354, 1995-2010.
4. Dawson, E. (1999) Mol. Med. Today, 5, 280.
5. Lindpaintner, K. (2003) J. Mol. Med., 81, 141-153.
6. Paul, N.W., Roses, A.D. (2003) J. Mol. Med., 81, 135-140.
7. Nebert, D.W. (1999) Clin. Genet., 56, 247-258.
8. Rioux, P.P. (2000) Am. J. Health-System Pharmacy, 57, 887-898.
9. Roses, A.D. (2000) Lancet, 355, 1358-1361.
10. Roses, A.D. (2000) Nature, 405, 857-865.
11. Shi, M.M. (2001) Clin. Chem., 47, 164-172.
12. Shi, M.M. (2002) Am. J. Pharmcogenom., 2, 197-205.
13. Shi, M.M., Bleavins, M.R., de la Iglesia, F.A. (1999) Mol. Diagnosis, 4, 343-351.
14. The SNP Consortium Ltd. (2000) Genotyping Technology Products User Requirements Survey (http://snp.cshl.org/news/user_survey. pdf).
15. Paul, N.W. (2001) Am. Family Physician, 63, 1704-1706.
16. Paul, N.W. (2003) Making Molecular Medicine: Historical, Theoretical, and Ethical Dimensions. Düsseldorf, Medizinische Fakultät der Heinrich-Heine-Universität, Habilitationsschrift.
17. Kollek, R., Feuerstein, G., Schmedders, M., van Aken, J. Eds (2004) Pharmakogenetik: Implikationen für Patienten und Gesundheitswesen. Anspruch und Wirklichkeit der "individualisierten Medizin". Baden-Baden, Nomos.
18. Lipton, P. (2003) Pharmacogenom. J., 3, 14-16.
19. The International SNP Map Working Group (2001) Nature, 409, 928-933.
20. Sotos, J.G., Rienhoff, H.Y., Block, G.D., Aulisio, M.P., Khoury, M.J., Ference, B.A., Chauhan, M.S., Izumo, S., Holtzman, N.A., Marteau, T.M. (2000) New Eng. J. Med., 343, 1496-1498.
21. Aparicio, S.A.J.R. (2000) Nature Genetics, 25, 129-130.
22. Bader, J.S. (2001) Pharmacogenomics, 2, 11-24.
23. Ewing, B., Green, P. (2000) Nature Genetics, 25, 232-234.
24. Holtzman, N.A., Marteau, T.M. (2000) New Eng. J. Med., 343, 141-144.
25. Roses, A.D. (1997) Arch. Neurol., 54, 1226-1229.
26. Bauer, M., London, E.D., Silverman, D.H., Rasgon, N., Kirchheiner, J., Whybrow, P.C. (2003) Pharmacopsychiatry, 36(Suppl 3), S215-221.
27. Holstein, A., Plaschke, A., Ptak, M., Egberts, E.H., El-Din, J., Brockmoller, J., Kirchheiner, J. (2005) Br. J. Clin. Pharmacol., 60, 103-106.
28. Kirchheiner, J., Brockmoller, J. (2005) Clin. Pharmacol. Ther., 77, 1-16.
29. Kirchheiner, J., Heesch, C., Bauer, S., Meisel, C., Seringer, A., Goldammer, M., Tzvetkov, M., Meineke, I., Roots, I., Brockmoller, J. (2004) Clin. Pharmacol. Ther., 76, 302-312.
30. Kirchheiner, J., Henckel, H.B., Franke, L., Meineke, I., Tzvetkov, M., Uebelhack, R., Roots, I., Brockmoller, J. (2005) Pharmacogenet. Genomics, 15, 579-587.
31. Kirchheiner, J., Henckel, H.B., Meineke, I., Roots, I., Brockmoller, J. (2004) J. Clin. Psychopharmacol., 24, 647-652.
32. Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.L., Licinio, J., Roots, I., Brockmoller, J. (2004) Mol. Psychiatry, 9, 442-473.
33. Vormfelde, S.V., Engelhardt, S., Zirk, A., Meineke, I., Tuchen, F., Kirchheiner, J., Brockmoller, J. (2004) Clin. Pharmacol. Ther., 76, 557-566.
34. ten Have, H. (1995) Hastings Center Report, 25, 13-19.
35. Gibbons, M., Limoges, C., Nowotny, H., Schwartzman, S., Scott, P., Trow, M. (1994) The New Production of Knowledge. The Dynamics of Science and Research in Contemporary Societies. London, Sage.
36. Nowotny, H., Scott, P., Gibbons, M. (2001) Re-Thinking Science: Knowledge and the Public in an Age of Uncertainty. Cambridge/Oxford, Polity.
37. Paul, N.W., Fangerau, H., Roots, I. (submitted) Cambridge Quarterly of Healthcare Ethics.
38. Chandler, A.D.j. (1990) Scale and Scope: The Dynamics of Industrial Capitalism. Cambridge, MA, Harvard University Press.
39. Rai, A.K. (2002) Soc. Philos. Policy, 19, 246-270.
40. Rothman, N., Wacholder, S., Caporaso, N.E., Garcia-Closas, M., Buetow, K., Fraumeni, J.F., Jr. (2001) Biochim. Biophys. Acta., 2, C1-10.
41. Gottesman, II, Gould, T.D. (2003) Am. J. Psychiatry, 160, 636-645.
42. Skuse, D.H. (2001) Br. J. Psychiatry, 178, 395-396.
43. Verhoeven, W.M., Tuinier, S. (2001) J. Neural. Transm., 108, 617-627.
44. Cordell, H.J. (2001) Ann. Hum. Genet., 65, 491-502.
45. Gauderman, W.J. (2002) Am. J. Epidemiol., 155, 478-484.
46. Gauderman, W.J. (2002) Stat. Med., 21, 35-50.
47. Risch, N., Teng, J. (1998) Genome Res., 8, 1273-1288.
48. Teng, J., Risch, N. (1999) Genome Res., 9, 234-241.
49. McGuffin, P., Royal College of Psychiatrists (1994) Seminars in Psychiatric Genetics. London, Gaskell : Distributed in North Ameica by American Psychiatric Press Inc.
50. Brockmoller, J., Kirchheiner, J., Schmider, J., Walter, S., Sachse, C., Muller-Oerlinghausen, B., Roots, I. (2002) Clin. Pharmacol. Ther., 72, 438-452.
51. Owen, M.J., Cardno, A.G. (1999) Lancet, 354(Suppl 1).
52. Bondy, B., Zill, P. (2001) World J. Biol. Psychiatry, 2, 178-183.
53. Staddon, S., Arranz, M.J., Mancama, D., Mata, I., Kerwin, R.W. (2002) Psychopharmacology (Berl), 162, 18-23.
54. Kirchheiner, J., Brosen, K., Dahl, M.L., Gram, L.F., Kasper, S., Roots, I., Sjoqvist, F., Spina, E., Brockmoller, J. (2001) Acta Psychiatr. Scand., 104, 173-192.
55. Issa, A.M. (2002) Nat. Rev. Drug Discov., 1, 300-308.
56. Bonvicini, K.A. (1998) Fam. Process, 37, 153-165.
57. Moldrup, C. (2002) Community Genetics, 4, 204-214.
58. Vaszar, L.T., Rosen, G.D., Raffin, T.A. (2002) Pharmacogenom. J., 2, 144-147.
59. Licinio, J., Wong, M.L. (2002) Pharmacogenom. J., 2, 343-344.
60. Schulze, B., Angermeyer, M.C. (2003) Soc. Sci. Med., 56, 299-312.
61. Paul, N.W. (2002) in Innovative Aspekte in der Prävention, (Gostomzyk, J.G. Ed, München. pp. 39-61.
62. Paul, N.W. (2003) Auswirkungen der Molekularen Medizin auf Gesundheit und Gesellschaft. Bonn, Friedrich Ebert Stiftung.
63. Paul, N.W. (2004) J. Cancer Res. Clin. Oncol., 130, 26.
64. Paul, N.W. Molekulare Prädiktion: Ein Weg zur Molekularen Prävention? in Innovative Aspekte in der Prävention, J.G. Gostornzyk, Editor. 2002: Munich. p. 39-61.
65. Annas, G.J. (1993) J. Am. Med. Ass. JAMA, 270, 2346-2350.
66. Judson, R., Stephens, J.C., Windemuth, A. (2000) Pharmacogenomics, 1, 15-26.
67. Annas, G.J., Elias, S. Eds (1992) Gene Mapping. Using Law and Ethics as Guides. New York, Oxford, Oxford University Press.
68. Clayton, E.W., Steinberg, K.K., Khoury, M.J., Thomson, E., Andrews, L., Kahn, M.J., Kopelman, L.M., Weiss, J.O. (1995) J. Am. Med. Ass., 274, 1786-1792.
69. Marshall, A. (1997) Nat. Biotech., 15, 954-957.
70. Lerer, B., Segman, R.H., Fangerau, H., Daly, A.K., Basile, V.S., Cavallaro, R., Aschauer, H.N., McCreadie, R.G., Ohlraun, S., Ferrier, N., Masellis, M., Verga, M., Scharfetter, J., Rietschel, M., Lovlie, R., Levy, U.H., Meltzer, H.Y., Kennedy, J.L., Steen, V.M., Macciardi, F. (2002) Neuropsychopharmacology, 27, 105-119.
71. Paul, N.W., Ganten, D. (2003) in Das genetische Wissen und die Zukunft des Menschen, (Honnefelder, L., Mieth, D., Propping, P., Siep, L., Wiesemann, C. Eds), De Gruyter, Berlin. pp. 103-114.